Luis Diaz: There is a good chance you can skip surgery
Luis Diaz, Head, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, shared on LinkedIn about a recent paper by Andrea Cercek et al. published in The New England Journal of Medicine:
“New study just published by our team at Memorial Sloan Kettering Cancer Center and led by Andrea Cercek. We show that if your early-stage tumor has a mismatch repair deficiency (a genetic test) then treatment with immunotherapy (PD-1 blockade) there is a good chance you can skip surgery as well as chemotherapy and radiation regardless of where the tumor originates. This work was supported by Swim Across America, Stand Up To Cancer, and National Cancer Institute (NCI).”
Nonoperative Management of Mismatch Repair–Deficient Tumors
Authors: Andrea Cercek et al.
In this post, Luis Diaz announced results from a new study led by Andrea Cercek at MSK, showing that patients with early-stage mismatch repair deficient (dMMR) tumors may be able to avoid surgery, chemotherapy, and radiation by using PD-1 blockade immunotherapy alone. This finding could shift treatment approaches across multiple cancer types. The research received support from Swim Across America, Stand Up To Cancer, and the National Cancer Institute.
Read about dMMR article on OncoDaily:
Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab
Also see more posts featuring Luis Diaz
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023